[Detection and interpretation of PD-L1 in urologic neoplasms]

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 are increasingly used for advanced urinary system tumors.
• PD-L1 expression analysis via immunohistochemistry is crucial for patient selection and efficacy prediction in ICI therapy.

Purpose of the Study:

• To review the current status of PD-L1 detection in urinary system tumors, primarily urothelial carcinoma.
• To discuss various antibody tests, interpretation challenges, and solutions for PD-L1 immunostaining.

Main Methods:

• Literature review of PD-L1 detection methods in urothelial carcinoma.
• Analysis of different antibody clones and detection platforms for PD-L1 expression.
• Summary of guidelines and expert opinions on PD-L1 interpretation.

Main Results:

• PD-L1 testing is a key biomarker for guiding immunotherapy in advanced urothelial carcinoma.
• Various antibody assays exist, each with specific protocols and potential for variability.
• Interpretation of PD-L1 staining presents challenges including scoring systems and tumor heterogeneity.

Conclusions:

• Standardized PD-L1 testing and interpretation are essential for optimizing immunotherapy in urinary system tumors.
• Addressing challenges in PD-L1 detection will improve patient stratification and treatment outcomes.
• Further research is needed to refine PD-L1 assays and predictive models for urothelial carcinoma.